BR112022007787A2 - Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer - Google Patents

Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer

Info

Publication number
BR112022007787A2
BR112022007787A2 BR112022007787A BR112022007787A BR112022007787A2 BR 112022007787 A2 BR112022007787 A2 BR 112022007787A2 BR 112022007787 A BR112022007787 A BR 112022007787A BR 112022007787 A BR112022007787 A BR 112022007787A BR 112022007787 A2 BR112022007787 A2 BR 112022007787A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
radiotherapy
tgfss
atm
Prior art date
Application number
BR112022007787A
Other languages
English (en)
Inventor
Lan Yan
S Lazorchak Adam
Original Assignee
Ares Trading Sa
Glaxosmithkline Intellectual Property No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa, Glaxosmithkline Intellectual Property No 4 Ltd filed Critical Ares Trading Sa
Publication of BR112022007787A2 publication Critical patent/BR112022007787A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INIBIÇÃO COMBINADA DE PD-1, TGFB E ATM JUNTAMENTE COM RADIOTERAPIA PARA O TRATAMENTO DE CÂNCER. A presente invenção refere-se a terapias de combinação úteis para o tratamento de câncer. Em particular, a invenção refere-se ao uso combinado de um inibidor de PD-1, um inibidor de TGFß, um inibidor de ATM e radiação para tratar câncer.
BR112022007787A 2019-11-01 2020-11-02 Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer BR112022007787A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962929379P 2019-11-01 2019-11-01
PCT/EP2020/080682 WO2021084124A1 (en) 2019-11-01 2020-11-02 COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
BR112022007787A2 true BR112022007787A2 (pt) 2022-07-05

Family

ID=73131710

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007787A BR112022007787A2 (pt) 2019-11-01 2020-11-02 Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer

Country Status (10)

Country Link
US (1) US20230044248A1 (pt)
EP (1) EP4051279A1 (pt)
JP (1) JP2023501971A (pt)
KR (1) KR20220095205A (pt)
CN (1) CN114615995A (pt)
AU (1) AU2020375161A1 (pt)
BR (1) BR112022007787A2 (pt)
CA (1) CA3154413A1 (pt)
IL (1) IL292613A (pt)
WO (1) WO2021084124A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3878461A4 (en) * 2018-11-09 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION OF TGF-BETA RECEPTOR FUSION PROTEIN AND USE THEREOF
WO2022258622A1 (en) * 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
WO2015011817A1 (ja) 2013-07-25 2015-01-29 住友ベークライト株式会社 医療機器
RU2021114500A (ru) 2014-02-10 2021-06-07 Мерк Патент Гмбх НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
RS62082B1 (sr) 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
RU2019106663A (ru) 2016-08-12 2020-09-14 Мерк Патент Гмбх Комбинированная терапия рака
WO2018208720A1 (en) 2017-05-09 2018-11-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies
MX2019013023A (es) 2017-05-12 2019-12-18 Jiangsu Hengrui Medicine Co Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
BR112020026862A2 (pt) 2018-06-29 2021-04-20 Gensun Biopharma, Inc. antagonistas antitumorais de reguladores de pontos de verificação imunológica
EP3820496A4 (en) 2018-07-09 2022-04-20 Precigen, Inc. FUSION CONSTRUCTS AND METHODS OF USE THEREOF
WO2020198066A1 (en) * 2019-03-22 2020-10-01 Duke University Compositions and methods for enhancing cancer immune checkpoint therapy

Also Published As

Publication number Publication date
JP2023501971A (ja) 2023-01-20
KR20220095205A (ko) 2022-07-06
CA3154413A1 (en) 2021-05-06
IL292613A (en) 2022-07-01
US20230044248A1 (en) 2023-02-09
WO2021084124A1 (en) 2021-05-06
CN114615995A (zh) 2022-06-10
AU2020375161A1 (en) 2022-05-19
EP4051279A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
BR112018071031A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2018005012A (es) Peptidos y peptidomimeticos en combinacion con agentes activadores de celulas t y/o inhibidores de puntos de control para el tratamiento del cancer.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112022007787A2 (pt) Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer
WO2019016772A3 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CL2022001794A1 (es) Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1.
BR112021021795A2 (pt) Moléculas de ligação a tigit e pd-1/tigit
AU2018271862A1 (en) Combination therapy
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
BR112022001690A2 (pt) Tratamento de tumores imunes evasivos
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]